Clinical Trials List
2025-03-01 - 2030-03-31
Phase III
Recruiting6
ICD-10C54.1
Malignant neoplasm of endometrium
ICD-10C54.2
Malignant neoplasm of myometrium
ICD-10C54.3
Malignant neoplasm of fundus uteri
ICD-10C54.9
Malignant neoplasm of corpus uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9182.0
Malignant neoplasm of corpus uteri, except isthmus
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- Meng-Ru Shen Division of Obstetrics & Gynecology
- Keng-Fu Hsu Division of Obstetrics & Gynecology
- 林語涵醫師 Division of Obstetrics & Gynecology
- 鄭雅敏 Division of Obstetrics & Gynecology
- 吳珮瑩 Division of Obstetrics & Gynecology
- 梁玉玲 Division of Obstetrics & Gynecology
- 黃蘭茵 Division of Obstetrics & Gynecology
- 周振陽醫師 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王韶靖醫師 Division of Obstetrics & Gynecology
- 范鈞婷醫師 Division of Obstetrics & Gynecology
- 劉芝谷醫師 Division of Obstetrics & Gynecology
- 呂亭芳醫師 Division of Obstetrics & Gynecology
- 陳蓉宣 Division of Radiology
- 許世典 Division of Obstetrics & Gynecology
- 黃曉峰醫師 Division of Obstetrics & Gynecology
- 石宇翔醫師 Division of Obstetrics & Gynecology
- 孫珞醫師 Division of Obstetrics & Gynecology
- 簡鴻仁醫師 Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- 楊思婷醫師 Division of Obstetrics & Gynecology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- 沈書慧 Division of Radiology
- Mei-Ju Chen Division of Ophthalmology
- Yen-Hou Chang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
504 participants